Across the Philippines, South Africa, Australia, and Singapore, Unnati Pharmax delivers the complete antiviral medicine range — covering HIV treatment and PrEP, Hepatitis B and C management, and COVID-19 antivirals — with WHO-GMP certified quality at prices that make sustained treatment genuinely accessible. Whether you are managing HIV in Manila, treating Hepatitis C in Cape Town, accessing COVID antivirals in Sydney, or seeking PrEP in Singapore — our products deliver the same clinical outcomes as branded alternatives at dramatically reduced cost.
FAQ 1: What is the HIV situation in Singapore and how does Unnati Pharmax's range serve Singapore patients?Singapore has a well-resourced HIV response — the Singapore government funds antiretroviral therapy for Singapore citizens and PRs through the public healthcare system, with subsidies available at restructured hospitals. However, significant gaps exist for specific populations: Employment Pass holders and other work visa categories may not qualify for the same subsidy levels; international students face coverage gaps; and Singapore's relatively conservative social environment creates stigma-related barriers particularly for MSM and sex workers who represent the majority of new HIV diagnoses. Singapore's HIV diagnosis rate has been relatively stable, with approximately 350-400 new cases annually — predominantly among MSM and heterosexual partners of affected individuals. The most common HIV presentation challenge in Singapore is late diagnosis, with about 30% of new diagnoses having CD4 below 200. For Singapore's HIV-positive community — including its significant international workforce and student population — Unnati Pharmax's affordable Tafero EM, Spegra, and Biktarvy generic provide reliable private access at significantly reduced cost versus Singapore private hospital antiretroviral pricing. FAQ 2: How does the Philippines' PhilHealth system address HIV treatment costs and where do the gaps lie?PhilHealth — the Philippine national health insurance programme — has provisions for HIV treatment through the HIV/AIDS Core Package, which covers outpatient HIV consultations, baseline investigations, and antiretroviral medications for enrolled members. However, significant gaps undermine comprehensive HIV treatment access. PhilHealth coverage for ARVs is limited to specific medications on the national formulary — newer preferred regimens like Dolutegravir-based therapy have been progressively added but formulary updates lag behind clinical guideline evolution. Coverage depth varies significantly between PhilHealth accredited treatment hubs (primarily in Metro Manila, Cebu, Davao) — rural patients often cannot access PhilHealth HIV services near their homes. Administrative requirements — HIV testing, registration, PhilHealth card maintenance — create barriers for marginalised populations who most need care. For the significant proportion of HIV-positive Filipinos who are informal workers without active PhilHealth membership, private access through affordable generic suppliers like Unnati Pharmax is the primary option for initiating and sustaining antiretroviral therapy. FAQ 3: What Hepatitis B burden exists in South Africa and how does Tafsure serve the South African market?South Africa carries a significant Hepatitis B burden — HBsAg prevalence of approximately 7-10% in the general adult population, with higher rates in sub-Saharan African populations of 8-12%. This high prevalence reflects perinatal and early childhood transmission patterns historically, before infant HBV vaccination became universal in South Africa's EPI (Expanded Programme on Immunisation) in 1995. South Africa's public health system provides HBV treatment through primary healthcare clinics for patients with active disease requiring treatment — using TDF (equivalent to Tavin) as the standard agent. However, access to the newer and safer TAF formulation (Tafsure) is limited in South Africa's public sector due to cost. In private healthcare — serving South Africa's insured population through medical aid schemes — Tafsure provides superior kidney and bone safety for HBV patients with pre-existing kidney disease or osteoporosis risk. Unnati Pharmax's generic Tafsure makes this improved TAF-based HBV therapy accessible in South Africa's private sector at dramatically reduced cost versus the price of brand Vemlidy from multinational manufacturers. FAQ 4: How does the COVID-19 antiviral landscape differ between Australia, Singapore, and the Philippines in 2026?COVID antiviral access varies significantly across our four common markets. Australia: Molnupiravir and Nirmatrelvir/Ritonavir (Paxlovid) are both PBS-listed for eligible high-risk patients, creating a well-functioning subsidised access system through GP prescribing and pharmacy dispensing — generic Molnulee supplements this for patients outside PBS eligibility or those who wish to maintain personal supply. Singapore: Both COVID antivirals are available through public healthcare and subsidised for eligible residents — Employment Pass holders and tourists face higher out-of-pocket costs; generic Molnulee serves Singapore's international population without full MOH subsidy access. Philippines: COVID antiviral access is significantly more limited — branded antivirals were available through government emergency use authorisation and limited private hospital supply, but access for the general population is inconsistent and expensive; generic Molnulee from Unnati Pharmax provides practical COVID antiviral access for Philippines private patients and high-risk individuals who cannot access government supply. The Philippines COVID access gap represents one of the most impactful applications of affordable generic antiviral supply in our four common markets. FAQ 5: What new antiviral products or formulations is Unnati Pharmax planning to add to serve Philippines, South Africa, Australia and Singapore customers?Unnati Pharmax continuously evaluates its product range to ensure our international customers have access to the most clinically important antiviral medicines as their patent status and generic manufacturing availability evolve. Products under evaluation for range expansion include: Sofosbuvir+Velpatasvir (generic Epclusa) for Hepatitis C Genotypes 2 and 3 — complementing our existing Resof L (Ledipasvir+Sofosbuvir) for Genotypes 1, 4, 5, 6; Entecavir as an alternative oral HBV therapy for patients who cannot tolerate TAF or TDF; and additional HIV combination regimens as patent expiries create generic manufacturing opportunities. We are also actively reviewing COVID antiviral developments as new direct-acting antiviral candidates complete trials. For institutional B2B customers in Philippines, South Africa, Australia, and Singapore interested in specific product additions, we welcome enquiries — our product development team evaluates customer-driven demand as a key input to range expansion decisions. Contact us via unnatipharmax.com, WhatsApp +91 82650 41513, or email Unnatipharmax@gmail.com to discuss specific product requirements for your market.HIV medicine Philippines Singapore 2026Hepatitis B South Africa Tafsure affordableCOVID